trial

The CAMPUS Project: Cholinergic Augmentation of Cognitive Deficits in Schizophrenia

NCTId NCT00206947
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 50 (estimated)
Sponsored by Birte Glenthoj
Primary completion 2005-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
50 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2002-12
Primary completion
2005-01
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
donepezil (5-10 mg/day)

Sponsors

Birte GlenthojLead Sponsor
Rigshospitalet, DenmarkCollaborator
Glostrup University Hospital, CopenhagenCollaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Collaborator

Investigators

1
Birte Glenthoj, MD, DMSc.Study Director

Sites

4 total
Copenhagen, DenmarkCopenhagen NV, DenmarkGlostrup Municipality, DenmarkHvidovre, Denmark

Linked catalysts

1
The CAMPUS Project: Cholinergic Augmentation of Cognitive Deficits in Schizophre — primary completion2005-01

Facts & assertions

4 sourced
Enrollment
50
Phase
PHASE2
Primary Completion Date
2005-01
Status
TERMINATED
relationships
The graph out of here
drug
donepezil (5-10 mg/day)
drug
lead_sponsor
Birte Glenthoj
company
collaborator
Rigshospitalet, Denmark
company
Glostrup University Hospital, Copenhagen
company
indication
Schizophrenia
indication
Schizophrenia
indication
Cognition Disorders
indication
investigator
Birte Glenthoj, MD, DMSc.
person